Activity Description:
We invite all participants to join us for this CME educational activity to explore emerging advances in pulmonary arterial hypertension (PAH) and the importance of early recognition, accurate risk assessment, and timely treatment are essential to improving patient outcomes.
Target Audience:
This course is designed for hospitalists, nurse practitioners, physician assistants, advance practice nurses, registered nurses, allied health professionals, physicians and residents.
Learning Objectives:
• Recognize common clinical clues suggesting pulmonary arterial hypertension (PAH) and right ventricular dysfunction in patients presenting with unexplained dyspnea.
• Explain how sotatercept differs mechanistically from conventional (pulmonary vasodilatory) PAH therapies. Recognize where, in the pulmonary hypertension treatment algorithm, current evidence would support sotatercept role.
• Describe the importance of early risk assessment and timely referral to a specialized pulmonary hypertension center.
SMC MGR D. Mohammad Flyer 11.17.26.pdf
Moderator:
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Accreditation:
The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support:
This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.
Disclosure:
The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. All of the relevant financial relationships listed for this individual have been mitigated. None of the planners, faculty, and those in control of this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
- 1.00 AMA PRA Category 1 Credit™HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
HCA Healthcare Continental Division designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance

Facebook
X
LinkedIn
Forward